3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
33
Lung Neoplasms
13
Breast Neoplasms
12
Colorectal Neoplasms
11
Ovarian Neoplasms
10
Recurrence
9
Neoplasms
9
Small Cell Lung Carcinoma
8
Neoplasm Metastasis
8
Head and Neck Neoplasms
8
Urinary Bladder Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Lymphoma, Large B-Cell, Diffuse
7
Prostatic Neoplasms
6
Carcinoma, Hepatocellular
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Diabetes Mellitus, Insulin-Dependent, 12
5
Carcinoma
5
Multiple Myeloma
4
Lymphoma, Follicular
4
Cholangiocarcinoma
4
Uterine Cervical Neoplasms
3
Recurrent Squamous Cell Lung Carcinoma
3
Oropharyngeal Neoplasms
3
Mouth Neoplasms
3
Mesothelioma
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Kidney Neoplasms
3
Interventions
Cyclophosphamide
82
fludarabine phosphate
68
Mycophenolic Acid
59
Whole-Body Irradiation
52
Peripheral Blood Stem Cell Transplantation
51
Tacrolimus
49
Melphalan
44
Etoposide
42
Busulfan
39
fludarabine
36
Rituximab
36
Filgrastim
36
Granulocyte Colony-Stimulating Factor
35
Brentuximab Vedotin
33
Cyclosporine
32
Doxorubicin
28
Methotrexate
27
Antilymphocyte Serum
27
Radiotherapy
24
Dacarbazine
19
Vinblastine
18
Nivolumab
18
Cytarabine
18
Prednisone
16
Carmustine
16
thymoglobulin
15
Stem Cell Transplantation
15
Sirolimus
15
Alemtuzumab
14
Vincristine
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Hodgkin Disease
×
durvalumab
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts